ESHG
In a trial of 23 Lynch syndrome patients, those who received the vaccine and developed neoantigen-specific T cells had a higher chance of remaining disease-free over 10 years.
ESHG: High-Risk Pediatric Cancer Survival More Than Doubles in Australian Precision Medicine Trial
Premium
More than 40 percent of patients in the Zero Childhood Cancer precision medicine program received a treatment recommendation based on their multiomic profiling results.
ESHG: UK Study Finds 6 Percent of Renal Cell Carcinoma Patients Carry Cancer Risk Variant
Researchers looked for pathogenic or likely pathogenic variants in 121 cancer risk genes in whole-genome sequencing data from 1,336 unselected RCC patients.
Diversity Problem Hinders Adoption of Polygenic Risk Scores, According to ESHG Panel
Polygenic risk scores have the potential to impact cancer screening, autoimmune disease testing, and therapeutics development, but more diverse data is needed.